Daliya Pencheva
Daliya is a rheumatology resident at the University Hospital “St. Ivan Rilski”, Sofia, Bulgaria. Her major interests are systemic lupus erythematosus, quality of life, patient-reported outcome measures, treat-to-target therapy. Daliya is a member of the EMEUNET Country Liaison Sub-Committee.
| Poster 1504 | Monday, 13.11.23 09.00 SLE – Treatment Poster II Author: Kyttaris, V (USA) Title: CHARACTERISTICS AND PRIOR TREATMENT JOURNEY OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) PATIENTS WHO WERE PRESCRIBED ANIFROLUMAB — OBSERVATIONS FROM THE AMERICAN RHEUMATOLOGY NETWORK (ARN) IN THE U.S  One of the first studies to characterize real-world utilization of anifrolumab in management of SLE patients. |
| Oral 1605 | Monday, 13.11.23 14.00 Antiphospholipid Syndrome Author:Yelnik, C (France) Title: COMPLEMENT ACTIVATION AS A MARKER OF THROMBOSIS RISK IN ANTIPHOSPHOLIPID ANTIBODY POSITIVE PATIENTS: PROSPECTIVE RESULTS FROM ANTIPHOSPHOLIPID SYNDROME ALLIANCE FOR CLINICAL TRIALS AND INTERNATIONAL NETWORKING (APS ACTION) CLINICAL DATABASE AND REPOSITORY (“REGISTRY”) In aPL-positive patients, markers of complement activation, specifically elevated C4d levels and positive mHAM test, are associated with a higher risk of thrombosis. |
| Poster 2262 | Tuesday, 14.11.23 09.00 SLE – Diagnosis, Manifestations, & Outcomes Poster III Author: Connelly, K (Australia) Title: IDENTIFYING IMPORTANT DOMAINS FOR INCLUSION IN A NOVEL TREATMENT RESPONSE MEASURE FOR SYSTEMIC LUPUS ERYTHEMATOSUS (TRM-SLE): RESULTS OF A MODIFIED DELPHI STUDY The study identifed domains to be considered for inclusion in the Treatment Response Measure for Systemic Lupus Erythematosus (TRM-SLE) – a novel clinical outcome assessment (COA) for SLE. |
| Poster 2278 | Тuesday, 14.11.23 09.00 SLE – Diagnosis, Manifestations, & Outcomes Poster III Author: Sieiro Santos, C (Spain) Title: PREGNANCY IN CONNECTIVE TISSUE DISEASES: A 30 YEAR FOLLOW-UP STUDY OF 465 PREGNANCIES FROM A SPANISH MONOCENTRIC REGISTRY Lupus activity was associated with unfavourable pregnancy outcomes, whereas exposure to HCQ had a protective effect during pregnancy. |
| Oral 2488 | Tuesday, 14.11.23 14.00 SLE – Treatment II: Nonrenal Author: Merrill, J (USA) Title: EFFICACY AND SAFETY OF ABBV-599 HIGH DOSE (ELSUBRUTINIB 60 MG AND UPADACITINIB 30 MG) AND UPADACITINIB MONOTHERAPY FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS: A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL In SLEek, ABBV-599HD (ELS 60 mg + UPA 30 mg) and UPA 30 mg demonstrated significant improvements in SLE disease activity and flares with acceptable safety through 48 weeks. |
| Oral 2588 | Wednesday, 15.11.23 11.00 SLE – Diagnosis, Manifestations, & Outcomes IV: Outcomes & Comorbidity Author: Bernatsky, S (Canada) Title: UPDATED ANALYSES OF CANCER INCIDENCE AND RISK FACTORS IN A LARGE INTERNATIONAL SLE COHORT This study produced updated estimates cancer risk in the largest-ever cohort of clinically confirmed incident SLE patients. |